{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T18:19:39Z","timestamp":1792865979694,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sociedade Brasileira de Reumatologia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Although Rheumatoid Arthritis (RA) extra-articular manifestations (ExtRA) occurrence has been decreasing over time, they are still a major mortality risk factor for patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To determine the prevalence of ExtRA in a large cohort, and its association with demographic and clinical variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Cross-sectional and observational study, based on a multi-centric database from a prospective cohort, in which 11 public rheumatology centres enrolled RA patients (1987 ARA or 2010 ACR-EULAR). Data collection began in 08-2015, using a single online electronic medical record. Continuous variables were compared using Mann\u2013Whitney <jats:italic>U<\/jats:italic>-test, and Fisher\u2019s exact test or chi-square test, as appropriate, were used for categorical variables. The level of significance was set at 5% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>1115 patients were included: 89% women, age [mean\u2009\u00b1\u2009SD] 58.2\u2009\u00b1\u200911.5\u00a0years, disease duration 14.5\u2009\u00b1\u200912.2\u00a0years, positive Rheumatoid Factor (RF, n\u2009=\u20091108) in 77%, positive anti-cyclic citrullinated peptide (ACPA, n\u2009=\u2009477) in 78%. Regarding ExtRA, 334 occurrences were registered in 261 patients, resulting in an overall prevalence of 23.4% in the cohort. The comparison among ExtRA and Non-ExtRA groups shows significant higher age (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009<jats:italic>0.001<\/jats:italic>), disease duration (p\u2009&lt;\u2009<jats:italic>0.001<\/jats:italic>), RF high titers (<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.018<\/jats:italic>), Clinical Disease Activity index (CDAI) (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009<jats:italic>0.001<\/jats:italic>), Disease Activity Index 28 (DAS 28) (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009<jats:italic>0.001<\/jats:italic>), and Health Assessment Questionnaire (HAQ) (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009<jats:italic>0.001<\/jats:italic>) in ExtRA group. Treatment with Azathioprine (<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.002<\/jats:italic>), Etanercept (<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.049)<\/jats:italic> Glucocorticoids (GC) (\u2018<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.002<\/jats:italic>), and non-steroidal anti-inflammatory drugs (NSAIDs) (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009<jats:italic>0.001<\/jats:italic>) were more frequent in ExtRA group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ExtRA manifestations still show an expressive occurrence that should not be underestimated. Our findings reinforce that long-term seropositive disease, associated with significant disability and persistent inflammatory activity are the key factors related to ExtRA development.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-023-00318-y","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T13:03:04Z","timestamp":1690376584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Extra-articular manifestations of rheumatoid arthritis remain a major challenge: data from a large, multi-centric cohort"],"prefix":"10.1186","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3547-5674","authenticated-orcid":false,"given":"Karina Rossi","family":"Bonfiglioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-5906","authenticated-orcid":false,"given":"Ana Cristina","family":"de Medeiros Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Carnieletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3910-4988","authenticated-orcid":false,"given":"Iv\u00e2nio","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7991-0231","authenticated-orcid":false,"given":"Diogo Souza","family":"Domiciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5665-4650","authenticated-orcid":false,"given":"Henrique Carri\u00e7o","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0444-738X","authenticated-orcid":false,"given":"Alisson","family":"Pugliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-1695","authenticated-orcid":false,"given":"Leticia Rocha","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3865-3739","authenticated-orcid":false,"given":"Maria Fernanda Resende","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-1723","authenticated-orcid":false,"given":"Rina Dalva Neubarth","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-2210","authenticated-orcid":false,"given":"Ana Paula Monteiro Gomides","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-7912","authenticated-orcid":false,"given":"Claiton Viegas","family":"Brenol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-3870","authenticated-orcid":false,"given":"Paulo","family":"Louzada-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria de F\u00e1tima Lobato","family":"da Cunha Sauma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6366-8401","authenticated-orcid":false,"given":"Sebasti\u00e3o Cezar","family":"Radominski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8182-5121","authenticated-orcid":false,"given":"Licia Maria Henrique","family":"da Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-569X","authenticated-orcid":false,"given":"Geraldo","family":"da Rocha Castelar-Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"issue":"1","key":"318_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/art.30100","volume":"63","author":"MP van der Linden","year":"2011","unstructured":"van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Classification of rheumatoid arthritis: comparison of the 1987 American college of rheumatology criteria and the 2010 American college of rheumatology\/European league against rheumatism criteria. Arthritis Rheum. 2011;63(1):37\u201342.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"318_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"318_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399.","journal-title":"Ann Rheum Dis"},{"key":"318_CR4","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"318_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s42358-021-00228-x","volume":"61","author":"KR Bonfiglioli","year":"2021","unstructured":"Bonfiglioli KR, da Mota LMH, de Medeiros Ribeiro AC, Kakehasi AM, Laurindo IMM, Giorgi RDN, et al. Recommendations of the Brazilian society of rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis. Adv Rheumatol. 2021;61(1):70.","journal-title":"Adv Rheumatol"},{"issue":"6","key":"318_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3899\/jrheum.101133","volume":"38","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova E, Crowson CS, Turesson C, Gabriel SE, Matteson EL. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995\u20132007 versus 1985\u20131994: a population-based study. J Rheumatol. 2011;38(6):983\u20139.","journal-title":"J Rheumatol"},{"issue":"1","key":"318_CR7","first-page":"62","volume":"29","author":"C Turesson","year":"2002","unstructured":"Turesson C, O\u2019Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol. 2002;29(1):62\u20137.","journal-title":"J Rheumatol"},{"issue":"1","key":"318_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/art.10705","volume":"48","author":"SE Gabriel","year":"2003","unstructured":"Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O\u2019Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48(1):54\u20138.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"318_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.berh.2007.05.007","volume":"21","author":"A Young","year":"2007","unstructured":"Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):907\u201327.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"318_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1590\/S0482-50042007000200002","volume":"47","author":"P Louzada-Junior","year":"2007","unstructured":"Louzada-Junior P. An\u00e1lise descritiva das caracter\u00edsticas demogr\u00e1ficas e cl\u00ednicas de pacientes com artrite reumat\u00f3ide no estado de S\u00e3o Paulo. Brasil Revista Brasileira de Reumatologia. 2007;47(2):84\u201390.","journal-title":"Brasil Revista Brasileira de Reumatologia"},{"issue":"4","key":"318_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102776","volume":"20","author":"FA Figus","year":"2021","unstructured":"Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20(4): 102776.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"318_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102735","volume":"20","author":"A Conforti","year":"2021","unstructured":"Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F, et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev. 2021;20(2): 102735.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"318_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/ard.62.8.722","volume":"62","author":"C Turesson","year":"2003","unstructured":"Turesson C, O\u2019Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62(8):722\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"318_CR14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1590\/S0482-50042012000500004","volume":"52","author":"MC Moura","year":"2012","unstructured":"Moura MC. Epidemiological profile of patients with extra-articular manifestations of rheumatoid arthritis from the city of Curitiba, South of Brazil. Rev Bras Reumatol. 2012;52(5):679\u201394.","journal-title":"Rev Bras Reumatol"},{"issue":"3","key":"318_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"318_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/annrheumdis-2012-202779","volume":"72","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, van der Helm-van Mil AH, Aletaha D, Bingham CO, Burmester GR, Dougados M, et al. EULAR definition of erosive disease in light of the 2010 ACR\/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis. 2013;72(4):479\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"318_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s42358-018-0017-9","volume":"58","author":"C-P da Rocha","year":"2018","unstructured":"da Rocha C-P, Vargas-Santos AB, de Albuquerque CP, Bertolo MB, Junior PL, Giorgi RDN, et al. The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil. Adv Rheumatol. 2018;58(1):9.","journal-title":"Adv Rheumatol"},{"issue":"8","key":"318_CR18","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/acr.22815","volume":"68","author":"RJ Desai","year":"2016","unstructured":"Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B, et al. Comparative risk of harm associated with the use of targeted immunomodulators: a systematic review. Arthritis Care Res. 2016;68(8):1078\u201388.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"318_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2009.146","volume":"301","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737\u201344.","journal-title":"JAMA"},{"issue":"10","key":"318_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/rheumatology\/keh299","volume":"43","author":"EH Choy","year":"2004","unstructured":"Choy EH. Two is better than one? Combination therapy in rheumatoid arthritis. Rheumatol. 2004;43(10):1205\u20137.","journal-title":"Rheumatol"},{"issue":"5","key":"318_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453\u201360.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"318_CR22","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, Lokke A, Bendstrup E, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76(10):1700\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"318_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","volume":"183","author":"AL Olson","year":"2011","unstructured":"Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183(3):372\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"318_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.04.061","author":"LDT Kawano-Dourado","year":"2020","unstructured":"Kawano-Dourado LDT, Bonfiglioli K, et al. Baseline characteristics and progression of a spectrum of interstitial lung abnormalities and disease in rheumatoid arthritis. Chest. 2020. https:\/\/doi.org\/10.1016\/j.chest.2020.04.061.","journal-title":"Chest"},{"issue":"2","key":"318_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ccm.2021.03.010","volume":"42","author":"L Kawano-Dourado","year":"2021","unstructured":"Kawano-Dourado L, Lee JS. Management of connective tissue disease-associated interstitial lung disease. Clin Chest Med. 2021;42(2):295\u2013310.","journal-title":"Clin Chest Med"},{"key":"318_CR26","unstructured":"Juge PA, Lee JS, Lau J, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021;57(2)."}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-023-00318-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-023-00318-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-023-00318-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T13:07:23Z","timestamp":1690376843000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-023-00318-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1186\/s42358-023-00318-y","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"16 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The REAL Study received ethical approval from the Universidade do Estado do Rio de Janeiro (the coordinating centre) Research Ethics Committee (registration number 45781015.8.1001.5259). Each participating site also obtained approval from their respective institution\u2019s ethics committee. All patients consented to participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final version of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ACMR: Personal fees and\/or nonfinancial support from Janssen, Pfizer, and AstraZeneca. AP: Personal fees and\/or nonfinancial support from Pfizer, AbbVie, UCB, BMS, Janssen, Lilly, Boehringer-Ingelheim. APC: No conflicts declared. APMG: Assistance for participation in events: Pfizer; CVB: personal or institutional support from AbbVie, Janssen and Pfizer; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Bristol-Myers Squibb and UCB. DSD: Personal fees and\/or non-financial support from Pfizer, UCB, AbbVie. GRCP: No conflicts declared. HCS: No conflicts declared. IAP: personal fee for lectures at AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Boehringer- Ingelheim, Janssen, Pfizer, Roche, Sandoz, Lilly and UCB. KRB: personal fees and\/or nonfinancial support from Pfizer, AbbVie, Roche, Novartis, Boehringer-Ingelheim. LRP: No conflicts declared. LMHM: personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Boehringer-Ingelheim, Janssen, Pfizer, Roche, Sandoz, Lilly and UCB. MFBRG: personal fees and\/or non-financial support from AbbVie, Bristol-Myers-Squibb, Janssen, Novartis, Pfizer, Roche and UCB. MFLCS: No conflicts declared. PL-J: Sponsored by Bristol-Myers Squibb, UCB, Pfizer, board Participation: Pfizer. RDNG: consulting fees, speaking fees, and support for international congresses from Roche, Pfizer, Bristol-Myers-Squibb, UCB Pharma, Eli-Lilly, AbbVie, Abbott, and EMS. SCR: Consulting fees, speaking fees, and support for clinical trials from AbbVie, Amgen, Bristol-Myers-Squibb, Lilly, Pfizer, and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}